Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Free Radic Biol Med ; 49(12): 1989-2000, 2010 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-20923704

RESUMO

The natural vitamin E analog α-tocopheryl phosphate (αTP) modulates atherosclerotic and inflammatory events more efficiently than the unphosphorylated α-tocopherol (αT). To investigate the molecular mechanisms involved, we have measured plasma levels of αTP and compared the cellular effects of αT and αTP in THP-1 monocytes. THP-1 cell proliferation is slightly increased by αT, whereas it is inhibited by αTP. CD36 surface expression is inhibited by αTP within hours without requiring transport of αTP into cells, suggesting that αTP may bind to CD36 and/or trigger its internalization. As assessed by gene expression microarrays, more genes are regulated by αTP than by αT. Among a set of confirmed genes, the expression of vascular endothelial growth factor is induced by αTP as a result of activating protein kinase B (PKB/Akt) and is associated with increased levels of reactive oxygen species (ROS). Increased Akt(Ser473) phosphorylation and induction of ROS by αTP occur in a wortmannin-sensitive manner, indicating the involvement of phosphatidylinositol kinases. The induction of Akt(Ser473) phosphorylation and ROS production by αTP can be attenuated by αT. It is concluded that αTP and αT influence cell proliferation, ROS production, and Akt(Ser473) phosphorylation in an antagonistic manner, most probably by modulating phosphatidylinositol kinases.


Assuntos
Antioxidantes/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Monócitos/efeitos dos fármacos , alfa-Tocoferol/análogos & derivados , alfa-Tocoferol/farmacologia , Animais , Antígenos CD36/metabolismo , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Perfilação da Expressão Gênica , Glibureto/farmacologia , Humanos , Monócitos/citologia , Monócitos/metabolismo , Fosforilação , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Espécies Reativas de Oxigênio/metabolismo , Suínos , Porco Miniatura , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/metabolismo , alfa-Tocoferol/sangue
2.
Clin Exp Pharmacol Physiol ; 37(5-6): 587-92, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20082629

RESUMO

1. Many studies have evaluated the effectiveness of alpha-tocopherol (vitamin E) in the development and progression of cardiovascular diseases, with conflicting results reported on the protective effect of this anti-oxidant. 2. The present study examined the effectiveness of a novel tocopheryl phosphate mixture (TPm) compared with that of alpha-tocopherol (TA) on key pro-inflammatory markers involved in atherogenesis, including interleukin (IL)-1beta, IL-6, IL-8, plasminogen activator inhibitor-1, tumour necrosis factor-alpha and C-reactive protein (CRP), as well as vascular function and lesion development in rabbits fed a 2% cholesterol diet. 3. Treatment with TPm, incorporated into the rabbit food at four doses ranging from 60 to 360 mg/kg chow, resulted in a significant reduction in plasma levels of all pro-inflammatory cytokines and biomarkers that appeared to be somewhat dose dependent. Conversely, treatment with TA, at a dose equivalent to the highest dose of TPm used, only decreased plasma levels of CRP, IL-6 and IL-8. Both TPm and TA treatment significantly improved vascular function to a similar extent, although TPm was more effective in reducing lesion development. 4. The reduction in these key pro-inflammatory markers appears to follow the improvement in the atherogenic state of the animals, indicating that the anti-inflammatory properties of TPm may be potentially beneficial in inflammatory disease states.


Assuntos
Antioxidantes/uso terapêutico , Aterosclerose/prevenção & controle , Citocinas/sangue , Hipercolesterolemia/complicações , alfa-Tocoferol/análogos & derivados , Animais , Antioxidantes/administração & dosagem , Aorta/efeitos dos fármacos , Aorta/patologia , Aorta/fisiopatologia , Aterosclerose/sangue , Aterosclerose/etiologia , Aterosclerose/imunologia , Aterosclerose/patologia , Biomarcadores/sangue , Citocinas/imunologia , Dieta Aterogênica , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Hipercolesterolemia/sangue , Hipercolesterolemia/imunologia , Hipercolesterolemia/patologia , Técnicas In Vitro , Lipídeos/sangue , Masculino , Coelhos , Resultado do Tratamento , Vasodilatação/efeitos dos fármacos , alfa-Tocoferol/administração & dosagem , alfa-Tocoferol/uso terapêutico
3.
Biochem Biophys Res Commun ; 318(1): 311-6, 2004 May 21.
Artigo em Inglês | MEDLINE | ID: mdl-15110789

RESUMO

The effect of a mixture of alpha-tocopheryl phosphate and di-alpha-tocopheryl phosphate (TPm) was studied in vitro on two cell lines, RASMC (from rat aortic smooth muscle) and human THP-1 monocytic leukaemia cells. Inhibition of cell proliferation by TPm was shown in both lines and occurred with TPm at concentrations lower than those at which alpha-tocopherol was equally inhibitory. TPm led in non-stimulated THP-1 cells to inhibition of CD36 mRNA and protein expression, to inhibition of oxidized low density lipoprotein surface binding and oxLDL uptake. In non-stimulated THP-1 cells, alpha-tocopherol had only very weak effects on these events. Contrary to alpha-tocopherol, TPm was cytotoxic to THP-1 cells at high concentrations. Thus, TPm is able to inhibit the major aggravating elements involved in the progression of atherosclerosis. The higher potency of TPm may be due to a better uptake of the molecule and to its intracellular hydrolysis, providing more alpha-tocopherol to sensitive sites. Alternatively, a direct effect of the phosphate ester on specific cell targets may be considered.


Assuntos
Arteriosclerose/metabolismo , Regulação para Baixo/efeitos dos fármacos , alfa-Tocoferol/análogos & derivados , alfa-Tocoferol/farmacologia , Animais , Aorta/citologia , Apoptose/efeitos dos fármacos , Arteriosclerose/patologia , Antígenos CD36/biossíntese , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Células Cultivadas , Fragmentação do DNA , Humanos , Inflamação/metabolismo , Inflamação/patologia , Lipoproteínas LDL/antagonistas & inibidores , Lipoproteínas LDL/metabolismo , Monócitos/citologia , Monócitos/efeitos dos fármacos , Monócitos/metabolismo , Músculo Liso Vascular/citologia , RNA Mensageiro/genética , Ratos , Transcrição Gênica/efeitos dos fármacos
4.
Ann N Y Acad Sci ; 1031: 405-11, 2004 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-15753182

RESUMO

The effect of a mixture of alpha-tocopheryl phosphate plus di-alpha-tocopheryl phosphate (TPm) was studied in vitro on two cell lines, RASMC (from rat aortic smooth muscle) and human THP-1 monocytic leukemia cells. Inhibition of cell proliferation by TPm was shown in both lines and occurred with TPm at concentrations lower than those at which alpha-tocopherol was equally inhibitory. TPm led in nonstimulated THP-1 cells to inhibition of CD36 mRNA and protein expression, to inhibition of oxidized low-density lipoprotein surface binding and oxLDL uptake. In nonstimulated THP-1 cells, alpha-tocopherol had only very weak effects on these events.


Assuntos
Arteriosclerose , Divisão Celular/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Inflamação , alfa-Tocoferol/análogos & derivados , alfa-Tocoferol/farmacologia , Animais , Aorta , Apoptose/efeitos dos fármacos , Antígenos CD36/genética , Linhagem Celular , Humanos , Leucemia/patologia , Lipoproteínas LDL/metabolismo , Músculo Liso Vascular/citologia , Músculo Liso Vascular/efeitos dos fármacos , Ratos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA